| Literature DB >> 34368781 |
Jacob J Adashek1, Alexey Goloubev2, Shumei Kato3, Razelle Kurzrock4.
Abstract
The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or immune-targeted cancer therapies improves the outcome of individual patients and increases the chances of successful drug approval. However, for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.Entities:
Mesh：
Year: 2021 PMID： 34368781 PMCID： PMC8336921 DOI： 10.1038/s43018-021-00204-w
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347